Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 11/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYBB | P04839 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302709 | 0.83 | NOX4 (0.61) | NOX4CYP2A13BRD4CYBB | |
| SCHEMBL17219872 | 0.83 | NOX4 (0.40) | NOX4CYBB | |
| SCHEMBL2212833 | 0.81 | NOX4 (0.61) | NOX4CYP2A13CYBB | |
| SCHEMBL1303126 | 0.80 | NOX4 (0.60) | NOX4CYP2A13CYBB | |
| SCHEMBL19956755 | 0.79 | NOX4 (0.58) | NOX4CYP2A13 | |
| SCHEMBL1302720 | 0.78 | NOX4 (0.56) | NOX4CYP2A13CYBB | |
| SCHEMBL1303271 | 0.78 | NOX4 (0.68) | NOX4CYBB | |
| SCHEMBL2213437 | 0.78 | NOX4 (0.62) | NOX4CYP2A13 | |
| SCHEMBL2208116 | 0.78 | NOX4 (0.62) | NOX4CYBB | |
| SCHEMBL1302625 | 0.77 | NOX4 (0.55) | NOX4CYBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342203-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-11-04 | — | — | EP | claimed |
| US-9006238-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-14 | — | — | US | claimed |
| US-20130158027-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-20 | — | — | US | claimed |
| US-8455486-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | claimed |
| US-20110178082-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | claimed |
| EP-2342203-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010035220-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | claimed |
| EP-2166009-A1 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | claimed |
| EP-2342203-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2342203-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-9006238-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006238-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006238-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20130158027-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20110178082-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178082-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178082-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035220-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2166009-A1 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166009-A1 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158027-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885KCNH2 2221/4885CYP2A13 207/4885 |
| US-20110178082-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885KCNH2 2221/4885CYP2A13 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.